Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain)

KOCAK, NURULLAH

doi:10.37783/CRJ-0336

Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain)

Nurullah KOÇAK (Ondokuzmayıs Üniversitesi, Göz Hastalıkları Departmanı, Samsun, Türkiye)

Güncel Retina Dergisi

12 0

Yıl: 2023 Cilt: 7 Sayı: 1 Sayfa Aralığı: 29 - 34 Metin Dili: Türkçe DOI: 10.37783/CRJ-0336 İndeks Tarihi: 17-05-2023

Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain)

Öz:

Günümüzde kullanılan birçok sistemik ilaç ya da bağımlılık yapıcı madde sonrası retinal toksisite izlenebilmektedir. İlaçlar retina üzerine etkilerini retina ve retina pigment epiteline direkt toksik etki, kristalin retinopati, fotoreseptör disfonksiyonu, kistoid makula ödemi, santral seröz koryoretinopati, üveitik etkiler ve vasküler sistem disfonksiyonu gibi farklı yollarla göstermektedir. Önemli bir altgrup olan vasküler disfonksiyon ise genellikle ilaçların endotel hasarı yaratan direk etkisi, protrombotik faktörlerde artış, immünkompleks oluşumu ve vazokonstrüksiyon yapıcı etkileri nedeniyle ortaya çıkar. Tedavide ana basamak patolojiye neden olan etkenin kullanımının kesilmesi ve/veya alternatifi ile değiştirilmesidir. Ek olarak gelişen retinal vasküler patolojinin nedenine yönelik medikal ya da intravitreal enjeksiyon tedavileri uygulanmalıdır.

Anahtar Kelime:

Medications Damaging Vascular Bed or Causing Microvasculopathy / Occlusion-2: Pathogenesis, Diagnosis, and Treatment (Gemcitabine, Fludarabine, Oral contraceptives, Heparin, Cocaine)

Öz:

Retinal toxicity can be observed during treatment with many systemic drugs and addictive substances used today. The drugs show their effects on the retina by different mechanisms such as direct toxicity to the retina and retina pigment epithelium, crystalline retinopathy, photoreceptor dysfunction, cystoid macular edema, central serous chorioretinopathy, uveitic effects, and vascular dysfunction. Vascular dysfunction, which is an important subgroup, occurs due to the direct effect of drugs on endothelium, increase in prothrombotic factors, and formation of immunocomplex and vasoconstrictive effects. The pr imary st ep in th e treatment is to cease the causative agent and replace it with an alternative. In addition, medical or intravitreal injection treatments should be applied according to the retinal vascular pathology.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik

1. Tsang SH, Sharma T. Drug-Induced Retinal Toxicity. Adv Exp Med Biol. 2018;1085:227-32.
2. Khan MJ, Papakostas T, Kovacs K, Gupta MP. Drug-induced maculopathy. Curr Opin Ophthalmol. 2020;31(6):563-71.
3. Valeshabad AK, Mieler WF, Setlur V, Thomas M, Shahidi M. Posterior segment toxicity following gemcitabine and docetaxel chemotherapy. Optometry and vision science: official publication of the American Academy of Optometry. 2015;92(5):e110.
4. Sheyman AT, Wald KJ, Pahk PJ, Freund KB. Gemcitabine associated retinopathy and nephropathy. Retin Cases Brief Rep. 2014;8(2):107-9.
5. Kovach JL. Gemcitabine-Induced Retinopathy. Retin Cases Brief Rep. 2018;12(3):240-1.
6. Tran TH, Desauw C, Rose C. Gemcitabine-induced retinopathy in a diabetic patient. Acta Ophthalmol. 2009;87(1):114-5.
7. Banach MJ, Williams GA. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. Arch Ophthalmol. 2000;118(5):726-7.
8. Batra S, Wadhwa J, Vaid AK, Sharma N. Old drugs: new complications. BMJ Case Rep. 2013;2013.
9. Jhaj G, Jhaj R, Shrier EM. Gemcitabine-Induced Retinopathy. Retina. 2017;37(11):e130-e1.
10. Warrell RP, Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4(1):74-9.
11. Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986;46(11):5953-8.
12. Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep. 1986;70(10):1225-8.
13. Bishop RJ, Ding X, Heller CK, 3rd, Illei G, Caruso R, Cunningham D, et al. Rapid vision loss associated with fludarabine administration. Retina. 2010;30(8):1272-7.
14. Chee YL, Culligan DJ, Olson JA, Molyneaux P, Kurtz JB, Watson HG. Sight-threatening varicella zoster virus infection after fludarabine treatment. Br J Haematol. 2000;110(4):874-5.
15. Moschos MM, Nitoda E. The impact of combined oral contraceptives on ocular tissues: a review of ocular effects. International Journal of Ophthalmology. 2017;10(10):1604.
16. Goldhaber SZ. Risk factors for venous thromboembolism. Journal of the American College of Cardiology. 2010;56(1):1-7.
17. Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertility and sterility. 2011;96(5):1175-89.
18. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011;76(7):636-52.
19. Stocco B, Fumagalli HF, Franceschini SA, Martinez EZ, Marzocchi-Machado CM, de Sá MFS, et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study. Medicine. 2015;94(4).
20. Urrutia RP, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, et al. Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstetrics & Gynecology. 2013;122(2 PART 1):380-9.
21. Jaais F, Habib Z. Unilateral superior ophthalmic vein thrombosis in a user of oral contraceptives. The Medical Journal of Malaysia. 1994;49(4):416- 8.
22. Donoghue JF, McGavigan CJ, Lederman FL, Cann LM, Fu L, Dimitriadis E, et al. Dilated thin-walled blood and lymphatic vessels in human endometrium: a potential role for VEGF-D in progestin-induced break-through bleeding. PLoS One. 2012;7(2):e30916.
23. Vastag O, Tornóczky J. Arterial occlusion in the ocular fundus induced by oral contraceptives. Orvosi hetilap. 1984;125(51):3121-5.
24. Leff S. Side-effect of oral contraceptives: occlusion of branch artery of the retina. Bulletin-Sinai Hospital of Detroit. 1976;24(4):227-9.
25. Cahill M, O’Toole L, Acheson R. Hormone replacement therapy and retinal vein occlusion. Eye. 1999;13(6):798-800.
26. Cheong J, Bucknall R. Retinal vein thrombosis associated with a herbal phytoestrogen preparation in a susceptible patient. Postgraduate medical journal. 2005;81(954):266-7.
27. Kirwan J, Tsaloumas M, Vinall H, Prior P, Kritzinger E, Dodson P. Sex hormone preparations and retinal vein occlusion. Eye. 1997;11(1):53-6.
28. Stowe 3rd G, Zakov ZN, Albert DM. Central retinal vascular occlusion associated with oral contraceptives. American journal of ophthalmology. 1978;86(6):798-801.
29. Vessey MP, Hannaford P, Mant J, Painter R, Frith P, Chappel D. Oral contraception and eye disease: findings in two large cohort studies. Br J Ophthalmol. 1998;82(5):538-42.
30. Song D, Nadelmann J, Yu Y, VanderBeek BL. Association of retinal vascular occlusion with women filling a prescription for female hormone therapy. JAMA ophthalmology. 2021;139(1):42-8.
31. Giovannini A, Consolani A. Contraceptive-induced unilateral retinopathy. Ophthalmologica. 1979;179(5):302-5.
32. Kayaalp O. Farmakolojiye Giriş, Rasyonel Tedavi Yönünden Tıbbi Farmakoloji Hacettepe-Taş Kitapçılık Ltd. Şti Ankara. 2002.
33. Greinacher A. CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. N Engl J Med. 2015;373(3):252-61.
34. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171-81.
35. Nomura Y, Kaneko M, Miyata K, Yatomi Y, Yanagi Y. Bevacizumab and Aflibercept Activate Platelets via FcγRIIa. Invest Ophthalmol Vis Sci. 2015;56(13):8075-82.
36. Julien S, Biesemeier A, Schraermeyer U. In vitro induction of protein complexes between bevacizumab, VEGF-A¹⁶⁵ and heparin: explanation for deposits observed on endothelial veins in monkey eyes. Br J Ophthalmol. 2013;97(4):511-7.
37. Nakao S, Yoshimitsu M, Kaizu Y, Wada I, Yamaguchi M, Sonoda K-H. Branch retinal artery occlusion in the untreated contralateral eye following aflibercept injections during heparin treatment: Possible contribution of a heparin-induced thrombocytopenia-like condition. American journal of ophthalmology case reports. 2019;16:100549.
38. Wang TY, Honeycutt EF, Tapson VF, Moll S, Granger CB, Ohman EM. Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. The American journal of medicine. 2012;125(12):1214-21.
39. Zagelbaum BM, Tannenbaum MH, Hersh PS. Candida albicans corneal ulcer associated with crack cocaine. American journal of ophthalmology. 1991;111(2):248-9.
40. Devenyi P, Schneiderman JF, Devenyi RG, Lawby L. Cocaine-induced central retinal artery occlusion. CMAJ: Canadian Medical Association Journal. 1988;138(2):129.
41. Sleiman I, Mangili R, Semeraro F, Mazzilli S, Spandrio S, Balestrieri GP. Cocaine-associated retinal vascular occlusion: report of two cases. The American journal of medicine. 1994;97(2):198-9.
42. Newman NM, DiLoreto DA, Ho JT, Klein JC, Birnbaum NS. Bilateral optic neuropathy and osteolytic sinusitis: complications of cocaine abuse. JAMA. 1988;259(1):72-4.
43. Van Stavern GP, Gorman M. Orbital infarction after cocaine use. Neurology. 2002;59(4):642-.
44. Isner JM, Chokshi SK. Cocaine and vasospasm. Mass Medical Soc; 1989. p. 1604-6.
45. Togna G, Tempesta E, Togna A, Dolci N, Cebo B, Caprino L. Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment. Pathophysiology of Haemostasis and Thrombosis. 1985;15(2):100-7.
46. Fandino J, Sherman JD, Zuccarello M, Rapoport RM. Cocaine-induced endothelin-1-dependent spasm in rabbit basilar artery in vivo. Journal of cardiovascular pharmacology. 2003;41(2):158-61.
47. Michaelides M, Larkin G. Cocaine-associated central retinal artery occlusion in a young man. Eye. 2002;16(6):790-2.
48. Kannan B, Balaji V, Kummararaj S, Govindarajan K. Cilioretinal artery occlusion following intranasal cocaine insufflations. Indian Journal of Ophthalmology. 2011;59(5):388.
49. Carroll WJ, Maganti N, Gill MK. Hypoperfusion of the deep capillary plexus associated with acute on chronic cocaine use. Am J Ophthalmol Case Rep. 2020;18:100684.

APA	KOCAK N (2023). Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). , 29 - 34. 10.37783/CRJ-0336
Chicago	KOCAK NURULLAH Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). (2023): 29 - 34. 10.37783/CRJ-0336
MLA	KOCAK NURULLAH Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). , 2023, ss.29 - 34. 10.37783/CRJ-0336
AMA	KOCAK N Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). . 2023; 29 - 34. 10.37783/CRJ-0336
Vancouver	KOCAK N Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). . 2023; 29 - 34. 10.37783/CRJ-0336
IEEE	KOCAK N "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain)." , ss.29 - 34, 2023. 10.37783/CRJ-0336
ISNAD	KOCAK, NURULLAH. "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain)". (2023), 29-34. https://doi.org/10.37783/CRJ-0336

APA	KOCAK N (2023). Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). Güncel Retina Dergisi, 7(1), 29 - 34. 10.37783/CRJ-0336
Chicago	KOCAK NURULLAH Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). Güncel Retina Dergisi 7, no.1 (2023): 29 - 34. 10.37783/CRJ-0336
MLA	KOCAK NURULLAH Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). Güncel Retina Dergisi, vol.7, no.1, 2023, ss.29 - 34. 10.37783/CRJ-0336
AMA	KOCAK N Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). Güncel Retina Dergisi. 2023; 7(1): 29 - 34. 10.37783/CRJ-0336
Vancouver	KOCAK N Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain). Güncel Retina Dergisi. 2023; 7(1): 29 - 34. 10.37783/CRJ-0336
IEEE	KOCAK N "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain)." Güncel Retina Dergisi, 7, ss.29 - 34, 2023. 10.37783/CRJ-0336
ISNAD	KOCAK, NURULLAH. "Vasküler Yatakta Hasar Yapan veya Mikrovaskülopati / Tıkanıklık yapan İlaçlar-2: Patogenez, Tanı ve Tedavi; (Gemsitabine, Fludarabine, Oral kontraseptifler, Heparin Kokain)". Güncel Retina Dergisi 7/1 (2023), 29-34. https://doi.org/10.37783/CRJ-0336